MerckProductServices - Pharmaceutical Products

CRIXIVAN^® (indinavir sulfate)

Please sign in using the form to the left to view the information resources and services for CRIXIVAN.

CRIXIVAN is available through the Merck Patient Assistance Program.

CRIXIVAN is listed on Merck Pregnancy Registries.

You can also visit crixivan.com

Ask a question about a Merck product or service.

Product Highlights

Learn more about CRIXIVAN^® (indinavir sulfate).

Please sign in using the form to
the left to access these resources.

Educational Resources

See for ALL Products

For Healthcare Professionals

For Your Patients

Journal Reprints

Please sign in using the form to
the left to access these resources.

Shafran Reprint Shafran SD, et al. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2006;6(6):421-5.
Five units per package
(Limit 1 per month)

Sherman Reprint Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30(6):908-14.
Five units per package
(Limit 1 per month)

Winston Reprint Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmaxokinetic interactions. J Antimicrob Chemother. 2005;56(1):1-5.
Five units per package
(Limit 1 per month)

No educational resources for patients are available at this time.

You can request a number of complimentary resources, where available, including:

Patient Educational Materials
Disease Management Tools, and more

Signing in using the form to the left will give you access to educational resources for other products.

Prescribing Information

CRIXIVAN^® (indinavir sulfate)

	Prescribing Information	[PDF]
	Patient Product Information	[PDF]
Viewing files designated with requires a PDF reader

ALL MERCK PRODUCTS

To see Prescribing Information for other Merck products, click on the letter corresponding to the product name.

Product Samples

CRIXIVAN^® (indinavir sulfate)
Samples cannot be obtained through Merck Product Services.

Signing in using the form to the left
will give you access to this service for other products.

View Important Product Information

eMedical Forum Webcasts

Upcoming Webcasts View All Webcasts

My Scheduled Webcasts

Attend a live, online educational program hosted by medical thought leaders, and interact with the speaker and the other participants.

Please sign in using the form to the left to access this service.

To view the details of upcoming webcasts that you have registered for, sign in now in the upper left corner of the page.

Archived Webcasts View All Archives

Access our archived eMedical Forum Webcasts, which are available for your viewing at any time.

Please sign in using the form to the left to access this service.

Important Product Information

CRIXIVAN in combination with other antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on two clinical trials of approximately 1 year's duration that demonstrated: (1) a reduction in the risk of AIDS-defining illness or death, and (2) a prolonged suppression of HIV RNA.

CRIXIVAN:

Does not cure HIV infection

Does not reduce the transmission of HIV

Should only be taken in combination with other drugs for HIV

CRIXIVAN is contraindicated in patients with clinically significant hypersensitivity to any of its components.

Drug Interactions With CRIXIVAN: Contraindicated Drugs

Drug Class	Drugs Within Class That are Contraindicated With CRIXIVAN	Potential Serious and/or Life-Threatening Reactions due to Inhibition of CYP3A4 by CRIXIVAN Resulting in Elevated Plasma Concentrations of These Drugs
Antiarrhythmics	Amiodarone	Cardiac arrhythmias
Ergot derivatives	Dihydroergotamine, ergonovine, ergotamine, methylergonovine	Acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues
Sedative/hypnotics	Midazolam, triazolam	Prolonged or increased sedation or respiratory depression
GI motility agents	Cisapride	Cardiac arrhythmias
Neuroleptics	Pimozide	Cardiac arrhythmias

COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA
FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. View the Merck/Schering-Plough privacy policy.
All other brand names are registered trademarks of Merck & Co., Inc.
MerckServices and MerckSource are registered trademarks of Merck & Co., Inc.
MerckProductServices and MerckMedicus are trademarks of Merck & Co., Inc.

Contact Us

Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products.
Get Started

The Merck National Service Center will be pleased to assist you Monday–Friday from 8:00 AM–7:00 PM ET. Adverse events and product-related emergencies will be handled at any time.

Get site technical support, or call 1-800-489-5119, for site technical issues.

CRIXIVAN® (indinavir sulfate)